Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 756

1.

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

Brandt MP, Gust KM, Bon D, Tsaur I, Thomas C, Neisius A, Haferkamp A, Herrmann E, Bartsch G.

Andrology. 2019 Jul;7(4):408-414. doi: 10.1111/andr.12666.

PMID:
31310057
2.

Development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection is independent of surgical approach: a single-center analysis.

Thomas C, Ziewers S, Thomas A, Dotzauer R, Bartsch G, Haferkamp A, Tsaur I.

Int Urol Nephrol. 2019 Apr;51(4):633-640. doi: 10.1007/s11255-019-02103-7. Epub 2019 Feb 22.

PMID:
30796729
3.

CT-guided nephrostomy-An expedient tool for complex clinical scenarios.

Brandt MP, Lehnert T, Czilwik T, Borgmann H, Gruber-Rouh T, Thalhammer A, Adam EH, Thomas C, Bartsch G, Haferkamp A, Vogl TJ, Tsaur I.

Eur J Radiol. 2019 Jan;110:142-147. doi: 10.1016/j.ejrad.2018.11.028. Epub 2018 Nov 23.

PMID:
30599852
4.

Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.

Thomas C, Brandt MP, Baldauf S, Tsaur I, Frees S, Borgmann H, Jäger W, Bartsch G, Schneider M, Dotzauer R, Neisius A, Haferkamp A.

Int Urol Nephrol. 2018 Oct;50(10):1821-1827. doi: 10.1007/s11255-018-1963-1. Epub 2018 Aug 17.

PMID:
30120678
5.

Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.

Nabar ND, Brandt MP, Thomas C, Tsaur I, Bartsch G, Jaeger W, Haferkamp A, Höfner T.

Minerva Urol Nefrol. 2019 Jun;71(3):205-216. doi: 10.23736/S0393-2249.18.03117-X. Epub 2018 Jul 18.

PMID:
30021426
6.

Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.

Jennewein L, Bartsch G, Gust K, Kvasnicka HM, Haferkamp A, Blaheta R, Mittelbronn M, Harter PN, Mani J.

Oncol Lett. 2018 Jun;15(6):9852-9860. doi: 10.3892/ol.2018.8597. Epub 2018 Apr 27.

7.

[Unexpected differential diagnosis of urachal cancer].

Ziewers S, Bartsch G, Thomas C, Kurosch M, Gheith K, Jäger W, Höfner T, Straub BK, Kloth M, Haferkamp A, Tsaur I.

Urologe A. 2018 Jun;57(6):714-716. doi: 10.1007/s00120-018-0672-9. German. No abstract available.

PMID:
29796699
8.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.

Gierth M, Zeman F, Denzinger S, Vetterlein MW, Fisch M, Bastian PJ, Syring I, Ellinger J, Müller SC, Herrmann E, Gilfrich C, May M, Pycha A, Wagenlehner FM, Vallo S, Bartsch G, Haferkamp A, Grimm MO, Roigas J, Protzel C, Hakenberg OW, Fritsche HM, Burger M, Aziz A, Mayr R.

Urol Int. 2018;101(1):16-24. doi: 10.1159/000488466. Epub 2018 May 2.

PMID:
29719296
9.

Nationwide analysis on the impact of socioeconomic land use factors and incidence of urothelial carcinoma.

Brandt MP, Gust KM, Mani J, Vallo S, Höfner T, Borgmann H, Tsaur I, Thomas C, Haferkamp A, Herrmann E, Bartsch G.

Cancer Epidemiol. 2018 Feb;52:63-69. doi: 10.1016/j.canep.2017.12.001. Epub 2017 Dec 11.

PMID:
29241107
10.

Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.

Vallo S, Rutz J, Kautsch M, Winkelmann R, Michaelis M, Wezel F, Bartsch G, Haferkamp A, Rothweiler F, Blaheta RA, Cinatl J Jr.

Oncol Lett. 2017 Nov;14(5):5513-5518. doi: 10.3892/ol.2017.6883. Epub 2017 Sep 4.

11.

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.

Vallo S, Köpp R, Michaelis M, Rothweiler F, Bartsch G, Brandt MP, Gust KM, Wezel F, Blaheta RA, Haferkamp A, Cinatl J Jr.

Oncol Lett. 2017 Jun;13(6):4085-4092. doi: 10.3892/ol.2017.5986. Epub 2017 Apr 5.

12.

Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain.

Brandt MP, Tsaur I, Vallo S, Krimphove M, Frellesen C, Vogl T, Hoefner T, Bartsch G, Haferkamp A, Thomas C.

Scand J Urol. 2017 Aug;51(4):342-344. doi: 10.1080/21681805.2017.1304988. Epub 2017 Apr 11. No abstract available.

PMID:
28398159
13.

What should be the patient's preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital.

Mani J, Vallo S, Brandt MP, Gust KM, Bartsch C, Daechert J, Tsaur I, Bartsch G, Haferkamp A.

Patient Prefer Adherence. 2016 Oct 28;10:2181-2187. eCollection 2016.

14.

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.

Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA.

Cent European J Urol. 2016;69(3):247-251. Epub 2016 Jun 30.

15.

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

Neisius A, Thomas C, Roos FC, Jäger W, Tsaur I, Bartsch G, Knoll T, Haferkamp A.

Urologe A. 2016 Oct;55(10):1291-1296. Review. German.

PMID:
27637181
16.

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.

Thomas C, Bartsch G, Walter C, Borgmann H, Brandt MP, Höfner T, Haferkamp A, Tsaur I.

Dent J (Basel). 2016 Aug 19;4(3). pii: E28. doi: 10.3390/dj4030028. Review.

17.

Strategy of robotic surgeons to exert public influence through Twitter.

Borgmann H, Woelm J, Nelson K, Gust K, Mager R, Reiter M, Schilling D, Bartsch G, Blaheta R, Haferkamp A, Tsaur I.

Int J Med Robot. 2017 Mar;13(1). doi: 10.1002/rcs.1739. Epub 2016 Feb 23.

PMID:
26914176
18.

Rare Case of Excessive Beta-Human Chorionic Gonadotropin Producing Intrascrotal Leiomyosarcoma: Diagnostic Pitfalls and Therapeutic Implications.

Brandt MP, Hoefner T, Gust KM, Ahrens M, Boettcher M, Kvasnicka HM, Bartsch G, Thomas C, Haferkamp A, Tsaur I.

Clin Genitourin Cancer. 2016 Aug;14(4):e409-12. doi: 10.1016/j.clgc.2016.01.009. Epub 2016 Jan 22. No abstract available.

PMID:
26873434
19.

Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro.

Makarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, Bartsch G, Haferkamp A, Blaheta RA.

Life Sci. 2016 Feb 15;147:137-42. doi: 10.1016/j.lfs.2016.01.039. Epub 2016 Jan 29.

PMID:
26827990
20.

Autophagy-associated proteins BAG3 and p62 in testicular cancer.

Bartsch G, Jennewein L, Harter PN, Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A, Mittelbronn M, Mani J.

Oncol Rep. 2016 Mar;35(3):1629-35. doi: 10.3892/or.2015.4505. Epub 2015 Dec 22.

PMID:
26707573
21.

Use of complementary and alternative medicine before and after organ removal due to urologic cancer.

Mani J, Juengel E, Arslan I, Bartsch G, Filmann N, Ackermann H, Nelson K, Haferkamp A, Engl T, Blaheta RA.

Patient Prefer Adherence. 2015 Oct 1;9:1407-12. doi: 10.2147/PPA.S90061. eCollection 2015.

22.

Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.

Bartsch G Jr, Mitra AP, Mitra SA, Almal AA, Steven KE, Skinner DG, Fry DW, Lenehan PF, Worzel WP, Cote RJ.

J Urol. 2016 Feb;195(2):493-8. doi: 10.1016/j.juro.2015.09.090. Epub 2015 Oct 13.

PMID:
26459038
23.

[Patient blood management: Current state of the literature].

Meybohm P, Fischer D, Schnitzbauer A, Zierer A, Schmitz-Rixen T, Bartsch G, Geisen C, Zacharowski K.

Chirurg. 2016 Jan;87(1):40-6. doi: 10.1007/s00104-015-3011-3. Review. German.

PMID:
26374647
24.

Globalization in Urology: A Bibliographical Analysis of Cross-Continent Publication between 2002 and 2012.

Mani J, Juengel E, Bartsch G, Filmann N, Ackermann H, Nelson K, Haferkamp A, Engl T, Blaheta RA.

Urol Int. 2015;95(3):281-7. doi: 10.1159/000438830. Epub 2015 Sep 9.

PMID:
26346650
25.

Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer.

Tsaur I, Biegel C, Gust K, Huesch T, Borgmann H, Brandt MP, Kurosch M, Reiter M, Bartsch G, Schilling D, Haferkamp A.

Int Braz J Urol. 2015 May-Jun;41(3):486-95. doi: 10.1590/S1677-5538.IBJU.2014.0304.

26.

Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.

Mani J, Antonietti P, Rakel S, Blaheta R, Bartsch G, Haferkamp A, Kögel D.

World J Urol. 2016 Feb;34(2):197-205. doi: 10.1007/s00345-015-1616-2. Epub 2015 Jun 23.

PMID:
26100943
27.

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J Jr.

Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002.

28.

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.

Tsaur I, Thurn K, Juengel E, Gust KM, Borgmann H, Mager R, Bartsch G, Oppermann E, Ackermann H, Nelson K, Haferkamp A, Blaheta RA.

J Exp Clin Cancer Res. 2015 May 14;34:43. doi: 10.1186/s13046-015-0161-6.

29.

Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).

Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A, Kögel D.

BMC Cancer. 2015 Apr 7;15:224. doi: 10.1186/s12885-015-1239-4.

30.

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.

Tsaur I, Hudak L, Makarević J, Juengel E, Mani J, Borgmann H, Gust KM, Schilling D, Bartsch G, Nelson K, Haferkamp A, Blaheta RA.

J Cell Mol Med. 2015 Aug;19(8):1795-804. doi: 10.1111/jcmm.12583. Epub 2015 Mar 26.

31.

Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.

Novotny V, Froehner M, May M, Protzel C, Hergenröther K, Rink M, Chun FK, Fisch M, Roghmann F, Palisaar RJ, Noldus J, Gierth M, Fritsche HM, Burger M, Sikic D, Keck B, Wullich B, Nuhn P, Buchner A, Stief CG, Vallo S, Bartsch G, Haferkamp A, Bastian PJ, Hakenberg OW, Propping S, Aziz A.

World J Urol. 2015 Nov;33(11):1753-61. doi: 10.1007/s00345-015-1502-y. Epub 2015 Feb 8.

PMID:
25663359
32.

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.

Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter M, Schilling D, Bartsch G, Haferkamp A, Blaheta RA.

Cancer Res Treat. 2015 Apr;47(2):306-12. doi: 10.4143/crt.2014.015. Epub 2014 Oct 13.

33.

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.

Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.

J Cell Mol Med. 2015 Feb;19(2):430-41. doi: 10.1111/jcmm.12471. Epub 2014 Dec 2.

34.

The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results.

Engel O, de Petriconi R, Volkmer BG, Gust KM, Mani J, Haferkamp A, Hautmann RE, Bartsch G.

J Negat Results Biomed. 2014 Nov 8;13:17. doi: 10.1186/1477-5751-13-17.

35.

CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro.

Tsaur I, Rutz J, Makarević J, Juengel E, Gust KM, Borgmann H, Schilling D, Nelson K, Haferkamp A, Bartsch G, Blaheta RA.

World J Urol. 2015 Jul;33(7):1051-6. doi: 10.1007/s00345-014-1389-z. Epub 2014 Sep 2.

PMID:
25179012
36.

Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?

Schmid M, Rink M, Traumann M, Bastian PJ, Bartsch G, Ellinger J, Grimm MO, Hadaschik B, Haferkamp A, Hakenberg OW, Aziz A, Hartmann F, Herrmann E, Hohenfellner M, Janetschek G, Gierth M, Pahernik Sh, Protzel C, Roigas J, Gördük M, Lusuardi L, May M, Trinh QD, Fisch M, Chun FK; PROMETRICS 2011 Research Group.

Ann Surg Oncol. 2015 Mar;22(3):1032-42. doi: 10.1245/s10434-014-4029-3. Epub 2014 Aug 28.

PMID:
25164037
37.

Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2.

Makarević J, Rutz J, Juengel E, Kaulfuss S, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.

PLoS One. 2014 Aug 19;9(8):e105590. doi: 10.1371/journal.pone.0105590. eCollection 2014.

38.

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.

Juengel E, Nowaz S, Makarevi J, Natsheh I, Werner I, Nelson K, Reiter M, Tsaur I, Mani J, Harder S, Bartsch G, Haferkamp A, Blaheta RA.

Mol Cancer. 2014 Jun 16;13:152. doi: 10.1186/1476-4598-13-152.

39.

MR-guided laser-induced thermotherapy in ex vivo porcine kidney: comparison of four different imaging sequences.

Vallo S, Eichler K, Kelly K, Schulz B, Bartsch G, Haferkamp A, Vogl TJ, Zangos S.

Lasers Surg Med. 2014 Sep;46(7):558-62. doi: 10.1002/lsm.22262. Epub 2014 Jun 6.

PMID:
24902949
40.

Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.

Juengel E, Makarević J, Reiter M, Mani J, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.

Neoplasia. 2014 Apr;16(4):291-300. doi: 10.1016/j.neo.2014.03.011.

41.

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.

Makarević J, Tawanaie N, Juengel E, Reiter M, Mani J, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.

J Cell Mol Med. 2014 Jul;18(7):1460-6. doi: 10.1111/jcmm.12299. Epub 2014 Apr 30.

42.

Is there an anti-androgen withdrawal syndrome for enzalutamide?

von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS.

World J Urol. 2014 Oct;32(5):1171-6. doi: 10.1007/s00345-014-1288-3. Epub 2014 Apr 2.

PMID:
24691670
43.

I publish in I edit?--Do editorial board members of urologic journals preferentially publish their own scientific work?

Mani J, Makarević J, Juengel E, Ackermann H, Nelson K, Bartsch G, Haferkamp A, Blaheta RA.

PLoS One. 2013 Dec 27;8(12):e83709. doi: 10.1371/journal.pone.0083709. eCollection 2013.

44.

Urinary functional outcomes in female neobladder patients.

Bartsch G, Daneshmand S, Skinner EC, Syan S, Skinner DG, Penson DF.

World J Urol. 2014 Feb;32(1):221-8. doi: 10.1007/s00345-013-1219-8. Epub 2013 Dec 7.

PMID:
24317553
45.

HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.

Juengel E, Meyer dos Santos S, Schneider T, Makarevic J, Hudak L, Bartsch G, Haferkamp A, Wiesner C, Blaheta RA.

Exp Biol Med (Maywood). 2013 Nov 1;238(11):1297-304. doi: 10.1177/1535370213498975. Epub 2013 Sep 4.

PMID:
24006305
46.

MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.

Pallua JD, Schaefer G, Seifarth C, Becker M, Meding S, Rauser S, Walch A, Handler M, Netzer M, Popovscaia M, Osl M, Baumgartner C, Lindner H, Kremser L, Sarg B, Bartsch G, Huck CW, Bonn GK, Klocker H.

J Proteomics. 2013 Oct 8;91:500-14. doi: 10.1016/j.jprot.2013.08.003. Epub 2013 Aug 14.

PMID:
23954705
47.

Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy.

Zehnder P, Moltzahn F, Daneshmand S, Leahy M, Cai J, Miranda G, Bartsch G Jr, Mitra AP, Skinner DG, Skinner EC, Gill IS.

BJU Int. 2014 Jan;113(1):65-9. doi: 10.1111/bju.12250. Epub 2013 Aug 13.

48.

Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.

Heidenreich A, Pfister D, Merseburger A, Bartsch G; German Working Group on Castration-Resistant Prostate Cancer (GWG-CRPC).

Eur Urol. 2013 Aug;64(2):260-5. doi: 10.1016/j.eururo.2013.05.021. Epub 2013 May 14. No abstract available.

PMID:
23706522
49.

[Cystectomy in the elderly patient].

Bartsch G, Gust K, Vallo S, Bartsch C, Tsaur I, Mani J, Haferkamp A.

Urologe A. 2013 Jun;52(6):821-6. doi: 10.1007/s00120-013-3196-3. Review. German.

PMID:
23604451
50.

Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.

Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S.

Urol Oncol. 2014 Feb;32(2):117-27. doi: 10.1016/j.urolonc.2012.08.017. Epub 2013 Mar 7.

PMID:
23477878

Supplemental Content

Loading ...
Support Center